ID   IGA2_HUMAN              Reviewed;         455 AA.
AC   P0DOX2;
DT   15-MAR-2017, integrated into UniProtKB/Swiss-Prot.
DT   18-JUL-2018, sequence version 2.
DT   07-APR-2021, entry version 16.
DE   RecName: Full=Immunoglobulin alpha-2 heavy chain {ECO:0000305};
DE   AltName: Full=Immunoglobulin alpha-2 heavy chain BUT {ECO:0000305|PubMed:416441};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   PROTEIN SEQUENCE, AND DISULFIDE BOND.
RX   PubMed=416441; DOI=10.1073/pnas.75.2.966;
RA   Torano A., Putnam F.W.;
RT   "Complete amino acid sequence of the alpha 2 heavy chain of a human IgA2
RT   immunoglobulin of the A2m (2) allotype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 75:966-969(1978).
RN   [2]
RP   GLYCOSYLATION AT ASN-162; ASN-207 AND ASN-246 AND ASN-442.
RX   PubMed=407576; DOI=10.1073/pnas.74.6.2301;
RA   Torano A., Tsuzukida Y., Liu Y.S., Putnam F.W.;
RT   "Location and structural significance of the oligosaccharides in human Ig-
RT   A1 and IgA2 immunoglobulins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 74:2301-2305(1977).
RN   [3]
RP   REVIEW ON FUNCTION AND SUBUNIT.
RX   PubMed=2241915; DOI=10.1042/bj2710285;
RA   Kerr M.A.;
RT   "The structure and function of human IgA.";
RL   Biochem. J. 271:285-296(1990).
RN   [4]
RP   REVIEW ON SOMATIC HYPERMUTATION.
RX   PubMed=17576170; DOI=10.1146/annurev.genet.41.110306.130340;
RA   Teng G., Papavasiliou F.N.;
RT   "Immunoglobulin somatic hypermutation.";
RL   Annu. Rev. Genet. 41:107-120(2007).
RN   [5]
RP   REVIEW ON IMMUNOGLOBULINS.
RX   PubMed=20176268; DOI=10.1016/j.jaci.2009.09.046;
RA   Schroeder H.W. Jr., Cavacini L.;
RT   "Structure and function of immunoglobulins.";
RL   J. Allergy Clin. Immunol. 125:S41-S52(2010).
RN   [6]
RP   REVIEW ON FUNCTION.
RX   PubMed=22158414; DOI=10.1038/nri3128;
RA   McHeyzer-Williams M., Okitsu S., Wang N., McHeyzer-Williams L.;
RT   "Molecular programming of B cell memory.";
RL   Nat. Rev. Immunol. 12:24-34(2012).
CC   -!- FUNCTION: Immunoglobulins, also known as antibodies, are membrane-bound
CC       or secreted glycoproteins produced by B lymphocytes. In the recognition
CC       phase of humoral immunity, the membrane-bound immunoglobulins serve as
CC       receptors which, upon binding of a specific antigen, trigger the clonal
CC       expansion and differentiation of B lymphocytes into immunoglobulins-
CC       secreting plasma cells. Secreted immunoglobulins mediate the effector
CC       phase of humoral immunity, which results in the elimination of bound
CC       antigens (PubMed:22158414, PubMed:20176268). The antigen binding site
CC       is formed by the variable domain of one heavy chain, together with that
CC       of its associated light chain. Thus, each immunoglobulin has two
CC       antigen binding sites with remarkable affinity for a particular
CC       antigen. The variable domains are assembled by a process called V-(D)-J
CC       rearrangement and can then be subjected to somatic hypermutations
CC       which, after exposure to antigen and selection, allow affinity
CC       maturation for a particular antigen (PubMed:20176268, PubMed:17576170).
CC       Ig alpha is the major immunoglobulin class in body secretions
CC       (PubMed:2241915). {ECO:0000303|PubMed:17576170,
CC       ECO:0000303|PubMed:20176268, ECO:0000303|PubMed:22158414,
CC       ECO:0000303|PubMed:2241915}.
CC   -!- SUBUNIT: Immunoglobulins are composed of two identical heavy chains and
CC       two identical light chains; disulfide-linked (PubMed:20176268).
CC       Monomeric or polymeric (PubMed:2241915). {ECO:0000303|PubMed:20176268,
CC       ECO:0000303|PubMed:2241915}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000303|PubMed:20176268,
CC       ECO:0000303|PubMed:22158414}. Cell membrane
CC       {ECO:0000303|PubMed:20176268, ECO:0000303|PubMed:22158414}.
CC   -!- CAUTION: This sequence is an example of a full-length immunoglobulin
CC       alpha-2 heavy chain. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   SMR; P0DOX2; -.
DR   iPTMnet; P0DOX2; -.
DR   jPOST; P0DOX2; -.
DR   MassIVE; P0DOX2; -.
DR   PeptideAtlas; P0DOX2; -.
DR   PRIDE; P0DOX2; -.
DR   OMA; CHAMPIL; -.
DR   Pharos; P0DOX2; Tdark.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0019814; C:immunoglobulin complex; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013106; Ig_V-set.
DR   InterPro; IPR013151; Immunoglobulin.
DR   Pfam; PF07654; C1-set; 2.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07686; V-set; 1.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00407; IGc1; 3.
DR   SMART; SM00406; IGv; 1.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   PROSITE; PS50835; IG_LIKE; 4.
DR   PROSITE; PS00290; IG_MHC; 2.
PE   1: Evidence at protein level;
KW   Adaptive immunity; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Immunity; Immunoglobulin;
KW   Immunoglobulin domain; Membrane; Repeat; Secreted.
FT   CHAIN           1..455
FT                   /note="Immunoglobulin alpha-2 heavy chain"
FT                   /id="PRO_0000439283"
FT   DOMAIN          1..95
FT                   /note="Ig-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          121..213
FT                   /note="Ig-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          227..322
FT                   /note="Ig-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          330..432
FT                   /note="Ig-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   REGION          1..115
FT                   /note="Variable (V) domain, involved in antigen
FT                   recognition"
FT                   /evidence="ECO:0000305|PubMed:416441"
FT   REGION          116..455
FT                   /note="Constant (C) domain"
FT                   /evidence="ECO:0000305|PubMed:416441"
FT   COMPBIAS        215..227
FT                   /note="Pro-rich"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00015"
FT   CARBOHYD        162
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:416441"
FT   CARBOHYD        207
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:416441"
FT   CARBOHYD        246
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:416441"
FT   CARBOHYD        320
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:416441"
FT   CARBOHYD        442
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:416441"
FT   DISULFID        22..95
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000303|PubMed:416441"
FT   DISULFID        141..200
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000303|PubMed:416441"
FT   DISULFID        216
FT                   /note="Interchain (with light chain)"
FT                   /evidence="ECO:0000303|PubMed:416441"
FT   DISULFID        224
FT                   /note="Interchain (with heavy chain)"
FT                   /evidence="ECO:0000303|PubMed:416441"
FT   DISULFID        225..282
FT                   /evidence="ECO:0000303|PubMed:416441"
FT   DISULFID        249..306
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000303|PubMed:416441"
FT   DISULFID        284
FT                   /note="Interchain (with heavy chain)"
FT                   /evidence="ECO:0000303|PubMed:416441"
FT   DISULFID        294
FT                   /note="Interchain (with heavy chain of another subunit)"
FT                   /evidence="ECO:0000303|PubMed:416441"
FT   DISULFID        352..415
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000303|PubMed:416441"
FT   DISULFID        454
FT                   /note="Interchain (with J chain)"
FT                   /evidence="ECO:0000303|PubMed:416441"
SQ   SEQUENCE   455 AA;  48934 MW;  FCAFE11CBF1C57AE CRC64;
     EVQLVETGGG LIQPGGSLRL SCAASGFTVS NHSMSWVRQA PGKALEWVSA IYRGGTTYYA
     DSVKGRFTIS RDDSRNTVYL QMNSLRAEDT AVYYCARDLA AARLFGKGTT VTVSSASPTS
     PKVFPLSLDS TPQDGNVVVA CLVQGFFPQE PLSVTWSESG QNVTARNFPP SQDASGDLYT
     TSSQLTLPAT QCPDGKSVTC HVKHYTNSSQ DVTVPCRVPP PPPCCHPRLS LHRPALEDLL
     LGSEANLTCT LTGLRDASGA TFTWTPSSGK SAVEGPPERD LCGCYSVSSV LPGCAQPWNH
     GETFTCTAAH PELKTPLTAN ITKSGNTFRP EVHLLPPPSE ELALNELVTL TCLARGFSPK
     DVLVRWLQGS QELPREKYLT WASRQEPSQG TTTYAVTSIL RVAAEDWKKG ETFSCMVGHE
     ALPLAFTQKT IDRLAGKPTH INVSVVMAEA DGTCY
//
